KYMR logo

Kymera Therapeutics, Inc. Stock Price

NasdaqGM:KYMR Community·US$4.1b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author
Create a narrative

KYMR Share Price Performance

US$59.89
13.84 (30.05%)
6.9% undervalued intrinsic discount
US$64.33
Fair Value
US$59.89
13.84 (30.05%)
6.9% undervalued intrinsic discount
US$64.33
Fair Value
Price US$59.89
AnalystConsensusTarget US$64.33

KYMR Community Narratives

AnalystConsensusTarget·
Fair Value US$64.33 6.9% undervalued intrinsic discount

Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent KYMR News & Updates

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates

Aug 14
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats

Jun 25

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week

May 13
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

May 08
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera Therapeutics, Inc. Key Details

US$44.7m

Revenue

US$290.9m

Cost of Revenue

-US$246.2m

Gross Profit

US$29.3m

Other Expenses

-US$275.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-3.85
Gross Margin
-550.56%
Net Profit Margin
-616.03%
Debt/Equity Ratio
0%

Kymera Therapeutics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet with very low risk.

2 Risks
0 Rewards
View Full Analysis

About KYMR

Founded
2015
Employees
218
CEO
Nello Mainolfi
WebsiteView website
www.kymeratx.com

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

U.S. Market Performance

  • 7 Days: -1.3%
  • 3 Months: 7.3%
  • 1 Year: 14.4%
  • Year to Date: 13.5%
Over the last 7 days, the market has dropped 1.3%, driven by a pullback of 2.1% in the Financials sector. In contrast to the last week, the market is actually up 14% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›